Abstract: Tissue engineering, the process of combining bioactive scaffolds often with cells to produce replacements for damaged organs, represents an enormous market opportunity. This review critically evaluates the commercialization potential of electrospun scaffolds for applications in stem cell biology, including tissue engineering. First, it provides an overview of pluripotent stem cells (PSCs) and their defining properties, pluripotency and the ability to self-renew. These cells serve as an important tool for engineering tissues, including for clinical applications. Next, we review the technique of electrospinning and its promise for fabricating cell culture substrates and scaffolds for directing tissue formation from stem cells and compare these scaffolds to existing technologies, such as hydrogels. We address the associated market for electrospun scaffolds for PSCs and its potential for growth along with highlighting the importance of 3D cell culture substrates for PSCs by analyzing the net capital invested in this market and the associated growth rate. This review finishes by detailing the current state of commercializing electrospun scaffolds along with pathways for translating these scaffolds from research laboratories into successful start-up companies and the associated challenges with this process.
Pluripotent Stem Cells and their Promise for Tissue Engineering Applications
Scientists had long hypothesized about the existence of stem cells in the body before confirming their existence experimentally [1] . These stem cells possess two distinct properties that distinguish them from other types of cells present in an organism [2] . The first property of a stem cell is the ability to become or differentiate into multiple types of cells. Their second property is the ability to self-renew, meaning that they can produce more stem cells. Both properties make stem cells a valuable tool for engineering tissues. The process of tissue engineering combines cells, biochemical cues, and biomaterial scaffolds as a way of producing substitutes for diseased or damaged tissues and it represents a lucrative market valued in the billions of dollars that is growing rapidly [3] . In terms of the history of how stem cells were discovered, the Canadian duo of Dr. Ernest Till and Dr. James McCulloch first identified mesenchymal stem cells in the 1960s [4] [5] [6] . However, these cells were limited in terms of the types of mature cells that they could become as they were derived from a specific tissue. Thus, scientists aimed to find a more versatile type of stem cell. One of the most desirable properties a stem cell can possess is pluripotency, meaning that these cells can produce any cell type found in the organism from which they were derived. Pluripotent stem cell lines are considered to be undifferentiated, reflecting this property, and these cells differentiate into mature phenotypes. The isolation and culture of pluripotent stem cells (PSCs) occurred much later than the initial discovery of stem cells with these cells being isolated from mouse embryos in 1981 [7] . These PSCs were termed embryonic stem cells (ESCs), reflecting the fact that they were derived from the embryo, which is an early stage of development that mammals go through in the process of becoming a mature organism. Deriving such pluripotent stem cells from human embryos was challenging -both in terms of finding sufficient donor embryos and successfully completing the isolation process. Thus, it was not until 1998 that human ESC lines were derived in the Thomson lab at the University of Wisconsin-Madison [8] . The generation of human ESCs lines then made it possible to engineer any type of tissue from these pluripotent cell lines.
Significant advances were then made in understanding how to derive mature functional cells from human ESCs, such cardiac tissue, bone, pancreas, and nervous tissue. These advances have resulted in two ESC-derived products being evaluated in clinical trials. The first product, oligodendrocyte progenitor cells derived from human ESCs, are being evaluated by Asterias Therapeutics (formerly Geron Corporation) in Phase I clinical trial for treating spinal cord injury [9] . Another clinical trial has examined the ability of human ESC-derived retinal pigmented epithelium to promote recovery in patients suffering from macular degeneration, which demonstrated promising results [10, 11] . Many neurological diseases and disorders lack true cures, making them attractive targets for cell therapies. In terms of pre-clinical work, it is anticipated that a Phase I clinical trial will be launched to evaluate the ability of human ESC-derived dopaminergic neurons to treat Parkinson's Disease in the near future [12] . Other promising targets for ESC-derived therapies include treating diabetes and heart disease [13, 14] .
However, several issues remain with the use of hESCs. The number of cell lines derived was limited under the Bush administration as the United States restricted funding for stem cell research. As a result, researchers began to investigate alternative ways of generating PSCs. In 2006, Takahashi and Yamanaka made a breakthrough discovery when they determined that four transcription factors, proteins which regulate the properties of cells, could be used to directly reprogram mouse fibroblasts back into a state of pluripotency [15] . They named the resulting cells induced pluripotent stem cells (iPSCs). This breakthrough was followed by the generation of human iPSC lines from fibroblasts [16, 17] . These cells generated excitement for several reasons. First, they now enabled the generation of pluripotent stem cells from specific patients, reducing the potential for immune rejection if the cells were used therapeutically. It was also now possible to generate iPSC lines from patients suffering from diseases, allowing the investigation into disease mechanisms and the ability to use these lines for applications in drug screening [18] . In Japan, the first clinical trial evaluating human iPSC-derived retinal pigment epithelial cells is underway [19] . More on the translation of PSC-derived therapies for clinical applications can be found in a recent review from Nature Reviews Molecular Cell Biology [20] .
While their pluripotency and their ability to self-renew serve as attractive properties for applications in tissue engineering, pluripotent stem cell lines, including ESCs and iPSCs, possess several limitations. One major concern is that their ability to replicate indefinitely can lead to tumour formation both in in vitro and in vivo settings. Thus, it is important to ensure that a chosen tissue engineering strategy promotes sufficient and mature differentiation of PSCs and avoids the presence of undifferentiated cells in the construct that is to be implanted, such as in the cell therapies currently being evaluated in clinical trials. Undifferentiated ESCs can be depleted using selection techniques like flow cytometry or antibiotic-mediated death in combination with genetically altered cell lines [21] . A pair of studies has indicated that iPSC lines can be selected that possess a reduced risk of tumour formation [22, 23] . As these cells can be maintained indefinitely in culture, confirming their genomic integrity with routine karyotyping will ensure that no harmful mutations have occurred in their DNA. Another approach to generating safe iPSC lines uses non-integrating microRNA technology developed by the Nagy lab at the University of Toronto, as the transient expression of the pluripotency genes results in cell lines without the risk of tumor formation [24] . Overall, PSCs represent a powerful tool for engineering tissues, which will be explained in the next section.
Current Status of PSCs for Tissue Engineering Applications
Early work from the Langer lab explored how combinations of polymer scaffolds and growth factors could be used to engineer different types of tissue from human ESCs [25] . Since then, numerous studies have explored how to engineer functional tissues from PSCs as these cells can become any type of tissue found in the body. The major challenge is determining the necessary set of physical and chemical cues necessary to guide these cells to form functional tissues [26] . Scientists often look to the chemical cues and physical structures present during tissue formation during the process of development as a starting point for designing proper scaffolding for directing the differentiation of PSCs [27] .
In terms of tissue engineering, the most commonly used scaffolds are hydrogels fabricated from biomaterials that are used to culture, expand, and differentiate PSCs [28] [29] [30] [31] . Hydrogels consist of cross-linked polymer networks that contain high water content. These hydrogels can be generated from both natural and synthetic polymers as their properties are selected to provide a supportive environment for controlling PSC behavior. While hydrogels are the most commonly used scaffolds for engineering tissues from PSCs, electrospinning has become an increasingly popular alternative fabrication technique for generating such scaffolds.
Fabrication of Fibrous Scaffolds using Solution and Melt Electrospinning
Electrospinning has been used for diverse tissue engineering applications in research laboratories [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . The technique spins highly charged polymer solutions into nanofibers or microfibers. In addition to the voltage field used to charge the polymer, other parameters play a key role in this process, including collection distance between the extruded polymer and the collector, the method of fiber collection, needle size used for extrusion and some other material-related parameters like molecular weight, solution concentration, viscosity and the type of solvent used to dissolve polymer or the melting point of the polymer [46] [47] [48] [49] [50] . A wide variety of polymers have been electrospun into scaffolds, including both natural and synthetic materials [51] . In terms of synthetic materials, poly (lacticco-glycolic acid) (PLGA) and poly (caprolactone) are popular choices for electrospinning. Natural biomaterials, including proteins like collagen, fibrin and ceramics, have also been electrospun. However, not all types of polymers can be electrospun as their intrinsic material properties dictate if and how the resulting fibers will form during the fabrication process. The electrospinning process can also alter the bioactivity of natural proteins, which is an important consideration when using electrospinning to fabricate scaffolds for PSC cultures. Electrospinning provides a unique opportunity to fabricate complex scaffolds that present the necessary chemical and physical cues for promoting differentiation of both ESCs and iPSCs [40, 44, 52, 53] . However, ensuring proper simultaneous presentation of chemical and physical cues using electrospinning can be challenging. The collection method for these fibers can be altered to produce different types of topography. Chemical cues can be incorporated into the polymer solution to enable the resulting fibers to present bioactive factors in a controlled fashion [54] [55] [56] . Two variants of the electrospinning process existsolution and melt. In solution electrospinning, the polymer is dissolved in a liquid solvent [32] with other components being mixed into polymer solution to further add bio-functionalities, including small molecules and macromolecules, such as proteins [34, 48, 55, [57] [58] [59] [60] [61] [62] [63] [64] . By contrast, melt electrospinning generates a liquid polymer by heating the material until it liquifies [53] . Both electrospinning techniques have been successfully applied to the field of tissue engineering as way to produce a variety of tissue types [65] [66] [67] [68] .
Tissue Engineering Applications of Fiber-Based Scaffolds
Solution electrospinning can produce engineered nanofiber scaffolds with multiple functionalities, including the controlled release of morphogens and the presentation of novel topographical cues. These nanofiber scaffolds have been combined with PSCs to engineer a variety of tissues, including neural, cardiac, and cartilage. The Willerth lab has done extensive work designing and fabricating such multifunctional scaffolds for promoting the neuronal differentiation of PSCs [47, 59, 69, 70] . For instance, Mohtaram et al. showed that encapsulation of retinoic acid inside engineered nanofibers with different topographies enhanced the neuronal differentiation of mouse iPSCs while guiding the outgrowth of neurites from these cells along the scaffold topography [55] . In terms of differentiating human iPSCs into neural tissue, aligned nanofiber scaffolds were encapsulated with the protein glial derived neurotrophic factor (GDNF), which was remained bioactive as it promoted the differentiation of human iPSCs into neurons [48] . These scaffolds can repair damaged cardiac tissue as reviewed recently [71] . Such electrospun nanofiber scaffolds can direct pluripotent stem cells to form functional cardiac tissue as shown in a 2016 study [72] . Nanofiber scaffolds have also been designed that promote the differentiation of PSCs into osteogenic lineages as a way to engineer bone tissue [73, 74] . Finally, nanofiber scaffolds generated using solution electrospinning can also direct PSCs to form chondrocytes, enabling the generation of cartilage [75] .
Other groups have used engineered nanofibers for other applications in directing PSC behavior as detailed by Higuchi et al. who performed an in depth review on the use of electropsun materials for culturing and differentiating PSCs [76] . Besides directing stem cell differentiation, electrospun scaffolds can be used as a tool for expanding pluripotent stem cells. In particular, defined electrospun scaffolds can serve as alternative to animal derived matrices, like Matrigel, which is often used to coat 2D substrates for expanding undifferentiated PSCs. 3D hydrogels have also been evaluated as a tool for PSC expansion as recently reviewed [77, 78] . One study determined that aligned and random PCL, PLGA, and poly (L-lactic acid) (PLLA) electrospun substrates supported the culture and expansion of human ESCs [79] . Recent work published in Acta Biomaterialia showed that electrospun polystyrene scaffolds could be used to culture undifferentiated hiPSCs under xeno-free conditions, providing an attractive alternative to Matrigel [80] . A recent Biomaterials papers demonstrated how solution electrospinning can generate fibrous scaffolds that mimic the extracellular matrix, enabling the expansion of human PSCs [81] . Such substrates address one of the major challenges in stem cell biology: producing sufficient quantities of cells for therapeutic applications. Although solution electrospinning remains an excellent technique for fabricating 2D and 3D substrates for expanding and differentiating PSCs, many challenges exist with this technique. These challenges include the use of organic toxic solvents, which can have negative effects on cell behavior, and the difficulties of controlling the architecture of the electrospun scaffolds. Another issue is ensuring that the mechanical properties of these scaffolds are consistent as they can vary during fabrication. These issues serve as the main obstacles to commercializing these technologies.
Melt electrospinning provides an attractive alternative to the more commonly used technique of solution electrospinning [39, 45, 82] . It opens new possibilities in the field of engineered electrospun scaffolds. Melt electrospinning produces engineered microfibers with a high degree of controllability and repeatability. Dr. Paul Dalton and his research group pioneered this technique and they have used melt electrospinning to fabricate scaffolds for a variety of tissue engineering applications [37, [83] [84] [85] [86] [87] [88] [89] [90] [91] . These applications include culturing fibroblasts and engineering replacements for damaged tendons. The Willerth lab in collaboration with Dr. Martin Jun's research group at Purdue University used a customized melt electrospinning setup to fabricate electrospun scaffolds with novel topographies for promoting the differentiation of PSCs into neural tissue [59, 69, 70, [92] [93] [94] [95] [96] . Such scaffolds can be designed and fabricated to meet needs of the consumer by altering parameters like needle size, collection distance and voltage field, which can be tuned to meet specifications provided by a customer [46] . For example, Mohtaram et al. used melt electrospun scaffolds with novel topography to direct neurite extension from differentiated neurons derived from human iPSCs [69] . These scaffolds relied on physical cues (in this case, fiber orientation) to differentiate PSCs. Although melt electrospinning avoids the two most common issues associated with solution electrospinning, which are the use of toxic solvents and the lack of reproducibility, there are still challenges to be addressed. Examples include finding suitable polymers that can be melted, how to incorporate bioactive molecules and drugs, how to electrospin natural biomaterials, and being able to generate fibers on the nanoscale.
Overall, both solution and melt electrospun scaffolds have shown great promise in the field of stem cell-based tissue engineering. Such scaffolds can be produced in a highly scalable manner and have utility for applications in PSC culture and differentiation into functional tissue. Such engineered products are in high demand as more research funding is being invested in the field of stem cell based tissue engineering. The next section addresses the market associated with such products and discusses the current state of the field and its future directions.
3D Substrates for PSC Culture
As mentioned earlier, PSCs can differentiate into any cell type found in human body. However, the differentiation process requires several complicated factors and specific environments or niches [92, [97] [98] [99] [100] [101] . These niches present biochemical, physical and mechanical signals to PSCs, which influence differentiation. Most current in vitro models for cell cultures seed aggregates of PSCs onto 2D polystyrene plates where they are treated with chemical cues to induce differentiation (102) . Such plates will not present or mimic the complex microenvironment of PSCs in vivo, and the cells often remodel their architecture to adapt to these 2D environments. Therefore, it is necessary to construct 3D surfaces that mimic the naturally occurring environment where PSCs proliferate, grow and differentiate.
Current micro and nanofabrication techniques can be implemented to generate 2D and 3D structures possessing the topography and surface features to support more physiologically relevant 3D stem cell cultures [103, 104] . Among such fabrication techniques is electrospinning. Therefore, modifying the surface of common 2D plates with electrospun fibers opens a new avenue for tissue engineering applications that involve the expansion and differentiation of PSCs that could eventually be used for therapeutic applications as described in the previous section.
The Current State of Commercializing 3D Electrospun Scaffolds and Associated Challenges
Many biotechnology companies use electrospinning to produce biomaterial scaffolds for stem cell research, medical devices and regenerative medicine as an alternative to using hydrogels. Electrospun scaffolds can provide a 3D niche for stem cells seeded upon or inside. However, the currently available scaffolds are limited to certain applications and have not been readily adopted as the industry standard. Several major challenges must be addressed. For instance, none of the current 3D cell culture systems have replaced 2D tissue culture products in terms of the largescale market. Many of the current 3D systems have issues in regards to scalability, reproducibility, sensitivity, and compatibility with high-throughput screening [105] . The market for 3D cell culture substrates was $438 million in 2013. This market is expected to grow to about $2.2 billion in 2019 based on a compound annual growth rate (CAGR) of 30.1%.
Various clients in health and education sectors benefit from 3D cell culture technology. For instance, pharmaceutical companies, biotechnology and life-science companies, hospitals, universities, laboratories, and research institutes are among the potential customers for 3D cell culture plates and associated projects. Biotechnology companies can generate revenue by licensing their technology to one of the current cell culture plate manufacturers. Alternatively, start-up companies can pursue joint ventures with a nanofabrication partner or a cell culture plate producer, generating revenue by selling biomimetic surfaces and plates through the sales and marketing network of the plate manufacturer. There are currently numerous well-established 2D cell culture manufacturers. Table 1 lists the most important companies in the field along with their annual revenue. Most of these companies produce 3D cell culture systems based on hydrogels, making it easier to translate promising technologies. Additionally, many small to medium-size companies are also active in the design and manufacture of 3D cell culture plates. However, none of these companies currently offer biomimetic surfaces suitable for PSC culture and differentiation. 
The Market for 3D Electrospun Scaffolds and Stem Cell Related Products
Currently, stem cell research is one of the most common applications of 3D cell cultures, and it has accounted for the largest demand for 3D cell culture substrates. For the purposes of this review, we will consider electrospun scaffolds to provide such a 3D environment due to their topography. Table 2 contains examples of companies involved with stem cell research along with their growth rate and financing status. Most of the market focuses on stem cell research, with less focus on cancer stem cells as evidenced by low product availability. Figure 1 shows the rapid growth in the total capital invested in stem cells research. In 2016, it reached around $16 billion. This market is expected to reach USD $18,329.37 million by 2020 due to increased spending in research and development. The methods for developing assays and related tools will progress and become more streamlined, and drug devel- opers will be able to identify problems with drug candidate leads at earlier stages of development, reducing the cost of drug discovery. This issue is one of the most pressing faced by small biopharmaceutical companies as over 90% of the compounds identified for neurological diseases in pre-clinical screens fail during clinical trials [106] . Globally, the regenerative medicine market is poised for intense growth as companies turn to regenerative medicine to treat unmet medical needs. Cell therapy products account for 76% of regenerative medicine products currently in development in Europe, Japan and the U.S. The role that 3D cell culture will play in regenerative medicine remains largely undefined, but can be compared to the testing of biologics during process development. If so, the data from the research applications will set the stage for later development in the field of 3D cell culture substrates pertaining to therapeutics.
Translating Technology from Research Laboratories into Start-up Companies
Electrospun scaffolds are easily fabricated in research laboratories. Most of electrospinning commercially available electrospinning set-up companies, such as Spraybase, provide customized systems. Electrospinning setups include a high voltage power supply, a computer numerical control (CNC) machine, a computer, needles, syringes, and customized collectors. These components are readily available in the commercial marketplace. While the technique of electrospinning is quite similar, translating these technologies to market has been challenging. In terms of demand for electrospun scaffolds, Figure 2 shows the total capital investment in North American companies that sell nanofiber-based products, such as Interface Biologics. Innovative, cutting edge, and promising technologies can be firstly designed and implemented in research laboratories. Intellectual property offices at Universities and research institutes have their own regulations and these offices work extensively with principal investigators, as well as graduate students, to file provisional patents, protecting their intellectual property. Once these technologies are patented, research labs can perform the necessary experiments to provide further proof-of-concept data to support the claims made in the patents. This process represents the initial steps necessary for commercialization of engineered scaffolds.
Collaborative projects in tissue engineering have produced numerous promising results as detailed earlier in this review which eventually support the commercialization of such technology. Patents and their associated publications serve as the main conceptual assets of start up companies working in this field. Once these assests are in place, start up companies can approach local angel investors to further increase the chance of bringing such products to large scale markets. Research laboratories, hospitals, life science and pharmaceutical companies serve as the potential customers for engineered and custom designed scaffolds. Such products are referred to as now-products since this field is extremely new and still faces serious challenges when it comes to successful commercialization. These challenges include the scale-up issues, regulatory affairs, and finding potential investigators to develop the products for market.
Conclusions and Future Recommendations
On-going pre-clinical and clinical trials are evaluating the use of stem cells to combat serious illnesses [107, 108] . Many challenges are associated with stem cell therapies, including achieving survival of these cells along with effectively controlling their differentiation into the desired phenotypes both in vitro and in vivo. 3D engineered electrospun biomaterial scaffolds can regulate the fate of PSCs for applications in tissue engineering and regenerative medicine. Two classes of electrospun scaffolds and their role in regulating the fate of PSCs were discussed in this review along with a detailed discussion on the market for such products. Many existing start-up companies aim to produce electrospun scaffolds which provide a relevant microenvironment for stem cell studies, along with drug discovery and toxicology research. Electrospinning technology can bridge the gap between traditional in vitro 2D cell culture systems and animal models, opening new avenues in commercialization of these products.
